A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal
Junction Cancer (FIGHT)
Basic Study Information
Purpose:
This is a global, randomized, double-blind, controlled study to evaluate the efficacy
of
bemarituzumab (FPA144) + mFOLFOX6 versus placebo + mFOLFOX6 in patients with FGFR2
selected
Gastric Cancer (as determined by prospective IHC FGFR2b overexpression and/or a ctDNA
blood
assay demonstrating FGFR2 gene amplification)
Location: University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James
P. Wilmot Cancer Center)
Study Contact Information
Study Coordinator: Medical Lead
Phone: (844) 333-5349
Email: FPA144004@fiveprime.com
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search